Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies

Next Previous
Trial Profile

CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti CD4 CAR T cell therapy-iCell Gene Therapeutics (Primary)
  • Indications Peripheral T-cell lymphoma; Sezary syndrome
  • Focus Adverse reactions; First in man
  • Sponsors iCell Gene Therapeutics

    • Most Recent Events

    • 10 Dec 2019 Results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology.
    • 18 Nov 2019 New source identified and integrated: ClinicalTrials.gov: US National Institutes of Health (NCT04162340).
    • 14 Nov 2019 According to an iCell Gene Therapeutics media release, data from this study will be presented at the 61st American Society of Hematology (ASH) Annual Meeting to be held December 7-10, 2019 in Orlando, Florida.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top